BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang J, Liu W, Li JC, Li M, Li B, Zhu R. Hepcidin Downregulation Correlates With Disease Aggressiveness And Immune Infiltration in Liver Cancers. Front Oncol 2021;11:714756. [PMID: 34277457 DOI: 10.3389/fonc.2021.714756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang J, Liu W, Song S, Li JC, Gan K, Shen C, Holzbeierlein J, Li B. The iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1080055] [Reference Citation Analysis]
2 Tong J, Lan X, Zhang Z, Liu Y, Sun D, Wang X, Ou-yang S, Zhuang C, Shen F, Wang P, Li D. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis. Acta Pharmacol Sin 2022. [DOI: 10.1038/s41401-022-01010-5] [Reference Citation Analysis]
3 Dong T, Zhang B, Zhang R, Wang C, Liu X, Wang F, Hao N, Tan K, Chang Y. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. Front Oncol 2022;12:963096. [DOI: 10.3389/fonc.2022.963096] [Reference Citation Analysis]
4 Joachim JH, Mehta KJ. Hepcidin in hepatocellular carcinoma. Br J Cancer 2022. [PMID: 35264787 DOI: 10.1038/s41416-022-01753-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Guo Q, Li L, Hou S, Yuan Z, Li C, Zhang W, Zheng L, Li X. The Role of Iron in Cancer Progression. Front Oncol 2021;11:778492. [PMID: 34858857 DOI: 10.3389/fonc.2021.778492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]